Guangdong Hybribio Biotech Co.,Ltd. (300639.SZ)
CNY 5.15
(0.0%)
CNY 5.15
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 615.23 Million CNY | -59.1% |
| 2022 | 1.5 Billion CNY | 98.88% |
| 2021 | 756.37 Million CNY | 134.4% |
| 2020 | 322.68 Million CNY | 187.27% |
| 2019 | 112.32 Million CNY | 3.84% |
| 2018 | 108.17 Million CNY | 9.55% |
| 2017 | 98.74 Million CNY | 27.43% |
| 2016 | 77.48 Million CNY | -3.28% |
| 2015 | 80.11 Million CNY | 95.11% |
| 2014 | 41.06 Million CNY | -48.44% |
| 2013 | 79.64 Million CNY | 104.41% |
| 2012 | 38.96 Million CNY | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 526.17 Million CNY | 8.66% |
| 2024 Q3 | 511.43 Million CNY | -2.8% |
| 2024 Q1 | 484.26 Million CNY | -21.29% |
| 2023 Q3 | 937.8 Million CNY | -8.94% |
| 2023 Q4 | 615.23 Million CNY | -34.4% |
| 2023 FY | 615.23 Million CNY | -59.1% |
| 2023 Q1 | 1.19 Billion CNY | -20.41% |
| 2023 Q2 | 1.02 Billion CNY | -13.98% |
| 2022 Q4 | 1.5 Billion CNY | 14.92% |
| 2022 FY | 1.5 Billion CNY | 98.88% |
| 2022 Q1 | 1.1 Billion CNY | 46.67% |
| 2022 Q2 | 1.3 Billion CNY | 17.99% |
| 2022 Q3 | 1.3 Billion CNY | -0.0% |
| 2021 Q3 | 762.66 Million CNY | 10.21% |
| 2021 Q2 | 692.02 Million CNY | 41.12% |
| 2021 Q4 | 756.37 Million CNY | -0.82% |
| 2021 FY | 756.37 Million CNY | 134.4% |
| 2021 Q1 | 490.36 Million CNY | 51.96% |
| 2020 Q1 | 165.03 Million CNY | 46.93% |
| 2020 Q4 | 322.68 Million CNY | 27.97% |
| 2020 FY | 322.68 Million CNY | 187.27% |
| 2020 Q2 | 244.33 Million CNY | 48.05% |
| 2020 Q3 | 252.15 Million CNY | 3.2% |
| 2019 Q1 | 94.41 Million CNY | -12.71% |
| 2019 FY | 112.32 Million CNY | 3.84% |
| 2019 Q3 | 96.07 Million CNY | -0.86% |
| 2019 Q4 | 112.32 Million CNY | 16.92% |
| 2019 Q2 | 96.9 Million CNY | 2.63% |
| 2018 FY | 108.17 Million CNY | 9.55% |
| 2018 Q4 | 108.17 Million CNY | 20.57% |
| 2018 Q3 | 89.71 Million CNY | -7.31% |
| 2018 Q2 | 96.79 Million CNY | 10.93% |
| 2018 Q1 | 87.25 Million CNY | -11.63% |
| 2017 Q3 | 85.78 Million CNY | 1.63% |
| 2017 Q4 | 98.74 Million CNY | 15.1% |
| 2017 FY | 98.74 Million CNY | 27.43% |
| 2017 Q1 | 51.6 Million CNY | -33.4% |
| 2017 Q2 | 84.41 Million CNY | 63.57% |
| 2016 Q1 | - CNY | 0.0% |
| 2016 Q2 | 75.23 Million CNY | 0.0% |
| 2016 Q4 | 77.48 Million CNY | 0.0% |
| 2016 FY | 77.48 Million CNY | -3.28% |
| 2015 FY | 80.11 Million CNY | 95.11% |
| 2014 FY | 41.06 Million CNY | -48.44% |
| 2013 FY | 79.64 Million CNY | 104.41% |
| 2012 FY | 38.96 Million CNY | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Dian Diagnostics Group Co.,Ltd. | 8.02 Billion CNY | 92.333% |
| Hangzhou Tigermed Consulting Co., Ltd. | 5.22 Billion CNY | 88.235% |
| Dirui Industrial Co.,Ltd. | 1.26 Billion CNY | 51.273% |
| Beijing Strong Biotechnologies, Inc. | 1.45 Billion CNY | 57.692% |
| Medicalsystem Biotechnology Co., Ltd. | 772.59 Million CNY | 20.368% |
| Maccura Biotechnology Co.Ltd | 1.5 Billion CNY | 59.196% |
| Guangzhou Wondfo Biotech Co.,Ltd | 1.15 Billion CNY | 46.829% |
| BGI Genomics Co., Ltd. | 3.6 Billion CNY | 82.953% |
| Amoy Diagnostics Co., Ltd. | 221.04 Million CNY | -178.332% |
| Shanghai Labway Clinical Laboratory Co., Ltd. | 1 Billion CNY | 38.886% |